The Chemours Company (NYSE:CC) had its price objective boosted by Barclays PLC from $55.00 to $58.00 in a note issued to investors on Monday. The firm currently has an “overweight” rating on the specialty chemicals company’s stock. Barclays PLC’s price objective points to a potential upside of 13.73% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of The Chemours from a “hold” rating to a “strong-buy” rating and set a $51.00 price target on the stock in a research note on Friday, July 14th. Jefferies Group LLC restated a “buy” rating and issued a $50.00 price target (up from $48.00) on shares of The Chemours in a research note on Thursday, July 13th. Citigroup Inc. raised their price target on shares of The Chemours from $45.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, August 4th. J P Morgan Chase & Co raised their price target on shares of The Chemours to $55.00 and gave the company an “overweight” rating in a research note on Friday, August 4th. Finally, UBS AG upgraded shares of The Chemours from a “sell” rating to a “neutral” rating and raised their price target for the company from $36.00 to $50.00 in a research note on Monday, August 7th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The Chemours presently has an average rating of “Buy” and a consensus price target of $54.33.

Shares of The Chemours (NYSE CC) opened at $51.00 on Monday. The Chemours has a one year low of $18.56 and a one year high of $58.08. The company has a quick ratio of 1.63, a current ratio of 2.19 and a debt-to-equity ratio of 5.07. The firm has a market cap of $9,490.00 and a P/E ratio of 18.50.

The Chemours (NYSE:CC) last posted its quarterly earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.11. The Chemours had a net margin of 13.07% and a return on equity of 121.47%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same period last year, the company posted $0.61 EPS. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. sell-side analysts anticipate that The Chemours will post 3.63 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Barclays PLC Increases The Chemours Company (CC) Price Target to $58.00” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/08/barclays-plc-increases-the-chemours-company-cc-price-target-to-58-00.html.

In related news, SVP David C. Shelton sold 5,908 shares of The Chemours stock in a transaction that occurred on Friday, October 13th. The shares were sold at an average price of $56.01, for a total transaction of $330,907.08. Following the sale, the senior vice president now directly owns 47,356 shares in the company, valued at approximately $2,652,409.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Amy Trojanowski sold 2,500 shares of The Chemours stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $46.03, for a total transaction of $115,075.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 77,142 shares of company stock worth $3,953,265. 1.14% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. Acrospire Investment Management LLC boosted its position in The Chemours by 3.4% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock worth $117,000 after buying an additional 100 shares during the period. Charter Trust Co. raised its holdings in The Chemours by 2.1% during the 2nd quarter. Charter Trust Co. now owns 5,720 shares of the specialty chemicals company’s stock worth $217,000 after purchasing an additional 120 shares during the last quarter. Cypress Capital Management LLC raised its holdings in The Chemours by 0.5% during the 2nd quarter. Cypress Capital Management LLC now owns 31,393 shares of the specialty chemicals company’s stock worth $1,190,000 after purchasing an additional 155 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in The Chemours by 0.6% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,921 shares of the specialty chemicals company’s stock worth $1,021,000 after purchasing an additional 167 shares during the last quarter. Finally, Commerce Bank raised its holdings in The Chemours by 3.0% during the 2nd quarter. Commerce Bank now owns 7,158 shares of the specialty chemicals company’s stock worth $272,000 after purchasing an additional 206 shares during the last quarter. Institutional investors and hedge funds own 73.23% of the company’s stock.

The Chemours Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for The Chemours (NYSE:CC)

Receive News & Stock Ratings for The Chemours Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Chemours Company and related stocks with our FREE daily email newsletter.